Form 4 for ZBIO Zenas BioPharma, Inc.
Accepted 2025-10-09 00:00:00 ET · period of report 2025-10-07 · accession 0001104659-25-098362 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-10-09 | 2025-10-07 | ZBIO | Harwin Peter Evan | Dir | P - Purchase | $19.00 | +316.2K | 2.21M | +17% | +$6.01M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-07 | P | A | 316,219 | $19.00 | 2,209,025 | I By Fairmount Healthcare Fund II L.P. | — | — | (F1) Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |